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Abstract
Objective
The aim of this study was to establish whether serum RANKL levels in early inflammatory arthritis (IA) were associated 
with rheumatoid arthritis (RA) diagnosis at follow-up, and to evaluate the added value of RANKL for RA diagnosis. 
Methods
Serum from 298 patients was collected. Demographic and clinical (swollen/tender joint counts, CRP, DAS28-CRP, RF, 
ACPA and shared-epitope data were recorded. Baseline ultrasound of 26 joints was performed, including total power 
Doppler (PD). An ELISA was used to measure RANKL. Predictors of progression were identified using multivariable 
logistic regression analysis. Area under the receiver operating characteristics (AUROC) was used to assess the 
performance of the prediction models and quantify the added value of RANKL in RA diagnosis.
Results
151 patients developed RA and 147 were non-RA (undifferentiated IA, other inflammatory diagnoses or non-persistent 
inflammation). RANKL levels were significantly higher in RA (median [IQR]: 474.1 [270.8–1430.6]) than in non-RA 
(median [IQR]: 301.0 [174.1–477.5]. Three clinical factors (age, SJC and PD) were identified by multivariable logistic 
regression with model performance AUROC of 77.9% (95% CI 72.1–83.8%). Adding RANKL resulted in a relative 
increase of 6.5% in the model classification performance of an AUROC of 83.0% (95% CI 77.9–88.1%).  
In ACPA-negative patients, the model performance increased from 77.6% (95% CI 69.5–85.7%) with clinical data 
only to 81.9% (95% CI 73.7–89.8%) with added value of RANKL and imaging.  
Conclusion
RANKL levels can predict RA diagnosis over clinical biomarkers alone, both seropositive and particularly in 
seronegative IA patients. 
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Introduction
Making the earliest diagnosis of rheu-
matoid arthritis (RA) is crucial to initi-
ate treatment and prevent further dis-
ease progression (1), including damage 
to the joints (2). The interactions be-
tween genes and environment are cen-
tral in all stages of RA (3). Leukocytes 
infiltrating the synovial membrane (4), 
a network of soluble mediators (5, 6) 
and the development of novel synovial 
blood vessels (i.e. angiogenesis) (7) are 
key features responsible for the devel-
opment of synovitis (8). 
Despite recent advances with the dis-
covery and integration of anti–citrul-
linated protein antibody (ACPA) in the 
RA classification criteria (9), there is 
still an unmet need for novel diagnostic 
biomarkers, notably for ACPA-negative 
(seronegative) disease. Seronegative 
inflammatory arthritis (IA) is a hetero-
geneous group, ranging from clinical 
presentations with a raised C-reactive 
protein (CRP) and erosions, to those 
with joint inflammation but not CRP or 
erosion.  
Our previous work (10) and others (11) 
has shown the importance of power 
Doppler ultrasonography (PDUS) in 
predicting persistent disease, particu-
larly in seronegative early IA. This is a 
sensitive tool which can detect synovi-
tis at the sub-clinical stage (12) as well 
as identify erosions at the stage where 
they are not detectable by conventional 
radiographs (13). Synovitis can there-
fore be accurately detected using PDUS 
in the small and large joints of patients 
with RA (14), with good correlation 
with histology and magnetic resonance 
imaging (MRI) (15, 16). PDUS is well 
tolerated by patients and can image a 
large number of joints at multiple time 
points over a relatively short period of 
time, with good reproducibility of data 
at the hand and wrist (17). Despite its 
utility, PDUS cannot predict all pro-
gression to RA.
Many groups have shown that known 
regulators of bone homeostasis include 
bone and cartilage turnover biomarkers 
such as the Receptor activator of nu-
clear factor kappa-Β ligand (RANKL), 
osteoprotegerin (OPG) (18, 19), pyridi-
noline (20), cartilage oligomeric matrix 
protein (COMP) (21), matrix metallo-
proteinase 3 (MMP-3) (22), carboxy-
terminal telopeptide of type I collagen 
(CTX-I) (23) and carboxy-terminal 
telopeptide of type II collagen (CTX-
II) (24). Some were related to radio-
graphic progression and differ in levels 
according to ACPA status (25, 26). In 
the receptor-activator-nuclear-factor-
κB axis, RANKL orchestrates bone de-
struction by inducing the differentiation 
of osteoclasts, whilst OPG is its decoy 
receptor and interferes with the binding 
of RANKL to its receptor RANK (27, 
28). RANKL and OPG expression (at 
mRNA level) in the synovial tissue of 
patients with RA showed a significant 
decrease for OPG whilst RANKL was 
increased (29-31). The mRNA ratio of 
RANKL:OPG was therefore defined 
as an indicator of osteoclast activation, 
favouring osteoclastogenesis in RA 
(32, 33). Using serum protein level the 
RANKL:OPG ratio was shown to pre-
dict subsequent joint destruction (34) 
and annual radiological progression 
over 11 years in RA (35). Additionally, 
serum RANKL levels alone may pre-
dict anti-tumour necrosis factor therapy 
induced remission in RA (36), whilst 
synthetic disease-modifying anti-rheu-
matic drugs (DMARDs) treatment sig-
nificantly reduces the RANKL:OPG 
ratio (37). 
However, there are no studies which 
use ultrasound and bone turnover as-
sessment for the prediction of progres-
sion to RA, especially in the ACPA 
negative group.
The aim of this study is to establish 
whether serum levels of bone turnover 
biomarkers in people with early inflam-
matory arthritis (IA) are associated with 
RA diagnosis at follow-up and to evalu-
ate the added value of RANKL with 
PDUS for the diagnosis of early RA. 
Methods
Patients
Consecutive patients attending the 
Leeds Early Arthritis clinic (EAC) were 
enrolled in the Inflammatory Arthritis 
disease CONtinuum register (IACON, 
approved by Local Ethics Committee 
REC: 09/H1307/98). This study recruit-
ed cases aged over 18, with an IA of 
less than 24 months symptom duration 
at first presentation, enrolled between 
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2010 and 2015. Demographic data (age, 
gender, symptom duration), clinical 
data (swollen and tender joint counts 
(SJC, TJC), disease activity score 
(DAS28-CRP) and laboratory charac-
teristics (CRP), rheumatoid factor (RF), 
ACPA and shared epitope (SE)) were 
collected. Patients were follow-up for 2 
years and RA classification established 
over this period using the EULAR 2010 
criteria. Alternative diagnosis included 
undifferentiated arthritis (UA), Psori-
atic arthritis (PsA), gout, non-persistent 
arthritis, osteoarthritis (OA) and palin-
dromic rheumatisms (PAL) as well as 
non-persistent symptoms. No patients 
included in our study had received a 
DMARD previous to the baseline visit/
samples. Clinical data were recorded 
in the register although not all patients 
had a full dataset (as detailed in Table 
I legend). All patients gave written, in-
formed consent.
Imaging
Ultrasound was performed at inclusion 
by experienced sonographers (RJW, 
ALT) using a GE E9 machine and em-
ploying either a 6–15 or 8–18 MHz lin-
ear array transducer as appropriate. For 
power Doppler examinations, the pulse 
repetition frequency was adjusted to 
provide maximal sensitivity at the low-
est possible value for each joint. Twen-
ty-six joints (bilateral elbows, wrists, 
MCP 2–3, PIP 2–3, knees, ankles and 
MTP 1-5) were scanned using EULAR 
recommendations for image acquisi-
tion (38). Images were scored using the 
semi-quantitative scoring system previ-
ously published (17). Summative scores 
were then calculated for the following 
parameters: power Doppler (PD), grey-
scale hypertrophy (GS) and erosions 
(ERO). Presence/absence of osteo-
phytes at each site was also recorded. 
Laboratory methods
The assessment of the laboratory bio-
markers was divided into 2 phases. 
First, in an exploratory cohort, six bio-
logical markers were studied. These 
were CTX I, CTX II, COMP, MMP3, 
RANKL and OPG, using blood and 
urine samples from RA and non-RA pa-
tients from our in-house clinical cohorts 
(n=40).
Subsequently, RANKL, OPG and 
MMP3 were studied in a larger cohort 
(n=117), using samples from addition-
al RA and non-RA patients to narrow 
down further the marker selection. In 
the last stage, a total of 298 serum sam-
ples were tested for RANKL only (in-
cluding the 2 previous groups).
Peripheral blood and mid-stream urine 
samples were collected at the inclusion 
visit. After centrifugation, the serum 
and urine supernatant were stored in 
-80°C until analysis. Serum was used 
to measure markers using commercial 
kits (enzyme-linked immunosorbent as-
says (ELISA): RANKL (BioVENDOR, 
CZR), OPG (eBioscience, Ltd., UK), 
CTX-I (Immunodiagnostic Systems, 
UK,), COMP and MMP3 (R&D sys-
tems, Biotechne, UK). Urine samples 
were used to measure urinary CTX-II 
(Immunodiagnostic Systems, UK) us-
ing creatinine (R&D systems, Biotech-
ne, UK) for normalisation.
Statistical analysis
Continuous variables were not normally 
distributed and therefore data were de-
scribed using median and interquartile 
range, and non-parametric tests were 
performed where appropriate. For ex-
ploring the data, Mann-Whitney U and 
Pearson’s Chi square tests were used as 
well as Spearman correlations. The level 
of significance for p-values was set at 
0.05. No adjustment was made for mul-
tiple testing in the exploratory analysis. 
Logistic regression was used to derive 
the unadjusted odds ratios (OR) for 
each clinical variables. Model selec-
tion was performed to select clinical 
variables that predict the diagnosis of 
RA. Area Under the Receiver Oper-
ating Characteristics (AUROC) was 
used to assess the model performance 
for classification of RA/non-RA, and 
the added value of RANKL was eval-
uated based on the improvement of 
AUROC when RANKL was included 
in the prediction models. To minimise 
bias caused by a small proportion of 
missing data, multiple imputation by 
chained equation was used to produce 
10 imputed datasets. Pooled modelling 
estimates and accompanying 95% con-
fidence intervals were generated ac-
cording to Rubin’s rule. The statistical 
software SPSS Statistics v. 24 and R v. 




A total of 298 consecutive patients at-
tending the Leeds Early Arthritis clinic 
were recruited into this study. 151 were 
classified as RA using the 2010 ACR/
EULAR criteria (delayed diagnosis was 
observed in 26 patients with a mean de-
lay of 9 months (range 3–21) and 147 
were non-RA, including UA (n=84), 
PsA (n=19), gout (n=2), SLE (n=2) in-
flammatory OA (n=18) and PAL (n=5) 
and non-persistent symptoms (n=17), 
with a mean delay for diagnosis of 18 
months (range 0–24). A description of 
demographics and clinical parameters 
is detailed in Table I. 
Exploratory biomarker analysis
Six markers (CTX I, CTX II, COMP, 
RANKL, OPG, MMP3) were initially 
tested on 40 samples including 26 RA 
and 14 non-RA patients. Analysis of se-
rum CTX I, urine CTX II and COMP 
did not suggest any discrimination be-
tween RA/non-RA groups and these 
markers were not investigated further 
(Fig. 1A). RANKL, OPG and MMP3 
showed non-significant trend for dif-
ferences between groups and were 
therefore tested on 77 additional serum 
samples (Fig. 1B; altogether RA=78, 
non-RA=39). In this second analysis, 
higher MMP3 levels were associated 
with RA (p=0.045) as well as higher 
OPG (p=0.029), however, both with a 
large overlap of distribution and many 
outliers in the non-RA group. Higher 
RANKL concentrations were observed 
in RA with a clear shift in distribution 
and limited outliers, despite not reach-
ing significance in this group (n=117, 
p=0.104). The median (IQR) values for 
the 1st and second analysis were similar 
for RANKL (RA: 335 [184-489] and 
373 [185–979] in the 1st and 2nd cohort 
respectively; non-RA: 305 [170–418] 
and 301 [175–454]). 
All 3 markers were significantly higher 
in ACPA-positive RA (n=53) (MMP3 
p=0.048; OPG p=0.032; RANKL 
p<0.001). MMP3 levels correlated with 
age and many other clinical parameters 
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with low rho values (<0.600) despite 
significant p-values: age (rho=0.413, 
p<0.0001), SJC (rho=0.271, p=0.003), 
DAS28-CRP (rho=0.246, p=0.012), 
CRP (rho=0.366, p=0.000), PDUS 
(rho=0.380, p=0.000), GS (rho=0.439, 
p=0.000), Osteophyte (rho=0.295, 
p=0.007). Similar correlations were 
observed for OPG: age (rho=0.389, 
p<0.0001), DAS28-CRP (rho=0.228, 
p=0.020), CRP (rho=0.232, p=0.012), 
PDUS (rho=0.217, p=0.019), Osteo-
phyte (rho=0.509, p=0.000). In con-
trast, RANKL was not associated with 
age/gender or any clinical (TJC, SJC, 
CRP, DAS28) or imaging (GS, PD) 
parameters, suggesting independent 
value as a potential biomarker. 
RANKL potential as a 
classification biomarker
In view of the previous results and 
the potential covariance between the 
level of OPG and MMP3 with demo-
graphic, clinical or imaging parameters, 
we choose to pursue RANKL. A final 
group including 298 individuals was 
selected from the early IA register, of 
whom 151 (51%) progressed to RA. 
The latter including alternative diagno-
ses established over 2 years of follow-
up (undifferentiated arthritis, other in-
flammatory arthritis) or non-persistent 
inflammation. All routinely used clini-
cal parameters were individually asso-
ciated with RA (Table I, ACPA, RF, SE, 
TJC, SJC, CRP, DAS 28, p<0.0001), as 
were imaging biomarkers (PDUS, GS, 
ERO, p<0.001; Osteophyte p=0.042). 
RANKL levels (pmol/L) were signifi-
cantly higher in RA (median [IQR]: 
474.1 [270.8–1430.6]) than in non-RA 
(median [IQR]: 301.0 [174.1–477.5] 
(Fig. 1C, p<0.0001). A ROC analysis 
for RANKL levels was performed and 
established that, with an AUROC of 
0.680 (95% CI 0.619–0.740, p<0.0001), 
a cut-off at a value of 500 can classify 
RA/non-RA with a specificity of 79%, 
allowing for sensitivity of 47% PPV of 
70% and NPV of 59% with an odds ra-
tio of 2.23. 
A multivariable logistic regression anal-
ysis was then performed to assess the 
value of RANKL for the classification 
of RA/non-RA. Autoantibodies (ACPA/
RF) were not included in the multivaria-
ble regression as they are part of the cri-
teria for RA classification. The compo-
nents of the DAS28 rather than the score 
itself were prioritised in this modelling. 
After model selection, 3 clinical param-
eters were sufficient to account for all 
associations with RA: age, SJC, and PD 
with classification performance AU-
ROC of 77.9% (95% CI 72.1–83.8%) 
(Table II). RANKL was a significant 
predictor for RA/non-RA (OR: 1.17, 
95% CI 1.09–1.28). Adding RANKL to 
3 previous parameters resulted a relative 
increase of 5.1% in the classification 
performance AUROC to 83.0% (95% 
CI 77.9–88.1%). 
Sero-negative group analysis
The same strategy was then used to 
Table I. Demographic, clinical and laboratory characteristics of patients: RA and non-RA.
Variable Non-RA n=147 RA n=151 p-value
Demographics
Age in years 49.0  (36.0–61.0) 59.0  (45.7–69.0) <0.0001
Female 103  (70.1%) 101  (66.9%) 0.618
Duration (months) 4.0  (3.0–8.0) 4.0  (3.0–6.0) 0.663
Never smoker* 42  (42.9%) 45  (38.1%) 0.425
Serology/SE
ACPA negative** 139  (95.2%) 54  (35.8%) <0.0001
RF negative** 129  (89.6%) 65  (43.3%) <0.0001
SE (negative/positive)** 79  (57.7%) 48  (32.9%) <0.0001
Clinical
SJC 1.0  (0.0–4.0) 4.0  (1.0–10.0) <0.0001
TJC 2.0  (1.0–4.0) 5.0  (2.0–11.5) <0.0001
CRP 5.0  (5.0–17.3) 9.3  (5.0–23.0) 0.008
DAS28-CRP& 3.1  (2.2–4.0) 4.2  (3.0–5.0) <0.0001
Imaging***
Power Doppler (PD) 1.0  (0.0–2.0) 4.0  (1.0–8.0) <0.0001
Grey-scale (GS) 12.0  (6.5–18.0) 15.0  (9.5–24.0) <0.0001
Osteophytes 2.0  (0.0–4.0) 3.0  (0.0–6.0) 0.042
Erosions (ERO) 0.0  (0.0–0.0) 0.0  (0.0–2.0) 0.002
Bone marker
RANKL pmol/L 301.0  (174.1–477.5)  474.1  (270.8–1430.6) <0.0001
Results are shown as median and (IQR) for quantitative data and as number of cases for qualitative 
data. * missing data in 82 participants; **missing data in 2 for ACPA, 4 for RF and 15 for SE; ***data 
available in 239 participants. & DAS28 used was 4 variables/CRP, missing the General Health visual 
analogue score in 73 cases due to non-relevance in early spondyloarthropathies.
Table II. Odds ratio (95% confidence intervals) for variables from unadjusted and adjusted 
logistic regression models applied to all patients (n=298). AUROC and 95% CI was re-
ported for adjusted models with clinical factors and RANKL. 
Variable in the model Unadjusted Adjusted Adjusted
  (3 variables) (4 variables)
Age 1.03 (1.02–1.05) 1.03 (1.01–1.05) 1.03  (1.01–1.05)
Sex 1.16 (0.71–1.89) 
Duration 0.99 (0.94–1.04) 
Smoking (ever/never) 0.90 (0.44–1.84) 
ACPA 35.67 (16.6–89.09) 
RF 11.25 (6.18–21.68) 
SE 2.78 (1.72–4.54)  
SJC 1.22 (1.14–1.31) 1.13 (1.05–1.23) 1.15 (1.07–1.26)
TJC 1.10 (1.05–1.15) 
CRP 1.02 (1.01–1.03) 
DAS28-CRP 1.82 (1.45–2.32) 
Doppler (PD total) 1.25 (1.15–1.37) 1.14 (1.05–1.26) 1.10 (1.01–1.21)
Grey-scale (GS total) 1.05 (1.02–1.08) 
Osteophytes 1.09  (1.01–1.19)  
Erosions (ERO) 1.45  (1.17–1.89)  
RANKL (per 100 pmol/L) 1.13  (1.08–1.19)   1.17 (1.09–1.28)
AUROC   77.9% (72.1%–83.8%) 83.0% (77.9%–88.1%)
NS: non-significant p-value
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Table III. Odds ratio (95% confidence intervals) for variables from unadjusted and adjusted logistic regression models applied to Sero-
negative patients (RA n=140, non-RA n=54). AUROC and 95% CI was reported for adjusted models with clinical factors and RANKL. 
Variable in the model Unadjusted Adjusted clinical Adjusted clinical + Adjusted clinical + Adjusted
    imaging  RANKL  All 
Age 1.04 (1.02–1.06) 1.03 (1.00–1.06) 1.03 (1.00–1.06) 1.03 (1.01–1.06) 1.03 (1.00–1.06)
Sex 0.90 (0.44–1.78)    
Duration 0.94 (0.87–1.02)    
Smoking (ever/never) 1.68 (0.5–5.34)    
SE 1.42 (0.74–2.72)    
SJC 1.27 (1.16–1.39)    
TJC 1.14 (1.08–1.20)    
CRP 1.01 (0.99–1.03)    
DAS28-CRP 2.36 (1.67–3.51) 2.08 (1.42–3.05) 1.94 (1.20–3.15) 2.44 (1.58–3.77) 2.06 (1.34–3.34)
Power Doppler (PD) 1.21 (1.11–1.35)   1.18 (1.01–1.38)   1.12 (1.03–1.24)
Grey-scale (GS) 1.05 (1.02–1.09)    
Osteophytes 1.12 (1.00–1.25)    
Erosions 1.31 (1.05–1.74)    
RANKL (per 100 pmol/L) 1.09  (1.03–1.16)     1.24  (1.13–1.38) 1.23  (1.12–1.39)
Overall % correct   77.6%  (69.5%–85.7%) 78.4%  (69.8%–86.5%) 81.3%  (73.4%–89.1%) 81.9%  (73.7%–89.8%)
NS: non-significant p-value.
Fig. 1. Biomarker levels in RA compared to non-RA. 
Tested 40 serum or urine samples as appropriate, RA=26, non-RA=14; 
Tested 117 serum samples, RA=78, non-RA=39. 
RANKL levels in RA (n=151) and non-RA patients (n=147) including UA (n=84) PsA (n=19), gout (n=2) non-persistent (n=17) SLE (n=2) inflammatory OA 
(n=18) and PAL (n=5); D) RANKL levels in RA ACPA+ (n=54) and ACPA- patients (n=97); E) RANKL levels in ACPA– RA (n=97) and non-RA (n=147); 
* p<0.05, **p<0.01, ***p<0.001, &trend
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investigate the value of RANKL in 
classification of RA (n=140) /non-RA 
(n=54) in ACPA-negative patients, as 
our ability to predict those who will de-
velop persistent, progressive disease is 
currently limited in this group. A ROC 
analysis showed an AUROC of 0.592 
(95% CI 0.496–0.681, p=0.05) a cut-off 
at a value of 450 can classify RA/non-
RA with a specificity of 71.5%, allow-
ing for sensitivity of 37% PPV of 33% 
and NPV of 75% with an odds ratio of 
1.30.
Logistic models were performed to se-
quentially demonstrate the independent 
value of adding imaging or RANKL 
to clinical data and then of combining 
clinical/imaging/RANKL. DAS28 was 
chosen to limit the number of param-
eters used (Table III). A model using 
only clinical data (age and DAS28) with 
the classification performance AUROC 
of 77.6% (95% CI 69.5–85.7%) was 1st 
defined. Adding imaging improved the 
model performance to 78.4% (95% CI 
69.8–86.5%). RANKL added to clinical 
data improved the model up to 81.3% 
(95% CI 73.4–89.1%). RANKL added 
to clinical and imaging data improved 
the model performance further to 
81.9% (95% CI 73.7–89.8%). 
Discussion
Following an exploratory phase aiming 
at selecting the bone turnover biomark-
er with the best discriminative capabili-
ties, our data showed that in early IA, 
progression to RA could be predicted 
with good accuracy using 4 variables 
combining demographic (age), clinical 
(SJC), imaging (PDUS) and serological 
biomarkers (RANKL). Furthermore, in 
ACPA-IA patients, who currently repre-
sent the group with the unmet need for 
a novel classification test, data suggest 
that progression can be best predicted 
with 3 variables: clinical (DAS), imag-
ing (PDUS) and serology (RANKL). 
Previous work has focussed on predict-
ing the outcome of early IA/UA using 
conventional clinical markers (39). 
More recently ACPA and ultrasound/
MRI have also been added in order to 
improve the sensitivity and specificity 
of such predictive models (10, 11, 40-
42). However, ACPA as a biomarker 
strongly predicts RA and, as such, 
other biomarkers add very little im-
provement in a combined model. Fur-
thermore, ACPA status being included 
in the classification criteria (43) prob-
ably explain why models containing 
ACPA do not detect the potential value 
of other markers. As such, our study 
showed a detectable +5.1% improve-
ment in classification adding RANKL 
over current classification using clini-
cal/demographic/imaging data. Despite 
overlapping CI, these data suggest that 
an ELISA for RANKL may offer ear-
lier classification for some patients. The 
value of US may results from detecting 
more patients with an ACPA- status. In-
deed, it remains difficult to predict a pa-
tient’s clinical course, especially early 
on in the seronegative disease, but the 
presence of positive PDUS was shown 
to significantly increase confidence in 
a diagnosis of persistent disease (10), 
while MRI has limited practicability as 
a predictive tool (44). In our study, we 
confirmed that PD had a small +0.8% 
improvement on classification of seron-
egative patients while RANKL showed 
a +3.7% increase. The combination of 
both only added a further +0.6% to the 
improvement brought in by RANKL 
alone. In this group, performing an 
ELISA for RANKL offer a small but 
none the less detectable improvement 
on classification.
The implications of using such a model, 
particularly in the ACPA negative group, 
lies in the ability to identify in the Early 
Arthritis Clinic those with a good prog-
nosis, thus avoiding over-treatment and 
potential drug related side effects. The 
limitation of our strategy was that we 
needed a large number of patients and 
achieved the selection of RANKL using 
the same patients for the discovery (co-
hort 1 and 2) and final analysis (cohort 
3). In terms of feasibility, tender and 
swollen joint counts are standard clini-
cal practice and US is increasingly used 
alongside the clinical assessment of pa-
tients. RANKL testing uses a simple se-
rum assay and can easily be performed 
by routine laboratory services. 
In conclusion, the value of RANKL 
over current biomarkers alone has been 
demonstrated, in both the seropositive 
(+5.1%) and sero-negative (+4.3%) IA 
groups. It is in this diagnostically chal-
lenging sero-negative group that new 
advances are especially welcome and 
the utility of RANKL shows encour-
aging preliminary results on which to 
build further work. 
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